Many of you already caught wind of OncoSec Medical Inc.'s ONCS when we posted it on the site on Tuesday at just 0.18 (see here)
Even though ONCS is up 22.65% since, Wall Street analysts at Roth Capital initiated coverage on ONCS with a buy rating Thursday and a $1.00 price target. Friday, OncoSec was,the 9th most traded of all the OTC stocks Friday with $770 thousand in volume.
ONCS is just getting started. (see here and here)
ONCS Share Structure:
PPS: $0.222 (current quote)
Outstanding Shares: 56.86 Million
Public Float: 33.11 Million
Cash a/o April 30: $6,569,626
Libilities a/o Apr 30: $2,998,038
Short Term Bullish Indicators
7 Day Average Directional Indicator
10 - 8 Day Moving Average Hilo Channel
20 Day Moving Average vs Price
20 - 50 Day MACD Oscillator
20 Day Bollinger Bands
Short Term Indicators Average: 100% (see here)
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from traditional cancer treatments. More information is available at www.oncosec.com
Basically, ONCS has developed a method to kill solid tumors cheaper, with fewer side effects than traditional tumor treatments in the head and neck area.
Just look at ONCS' recent and future schedule. Punit Dhillon, President and CEO of OncoSec, will be on the road presenting a corporate overview as well as scientific findings from thier clinical trials, including its portfolio and investment highlights, at the following conferences:
- Bio International Convention, Boston, MA, June 18-21, 9:00 am ET
- Marcum MicroCap Conference, New York, NY, June 20, 11:30 am ET
- OneMedForum NY 2012, New York, NY, July 12, Time to be confirmed
- 2nd European Post-Chicago Melanoma Meeting, Munich, Germany, June 21-22
- 10th Annual Vaccines Research and Development: All Things Considered Conference, San Francisco, CA, July 10, 11:05 am PT
- 8th International Conference on Head and Neck Cancer, Toronto, Canada, July 22-24
The road show ends in Toronto where ONCS will present the preliminary data sets from the completed phase III recurrent head and neck cancer studies carried out in the U.S. at the 5th International Head and Neck Cancer Conference taking place July 21-25.